Despite KRAS G12V being a common mutation in cancer, no direct inhibitors currently exist. Stanland et al. demonstrate that an EGFR-directed RNAi platform, EFTX-G12V, selectively targets KRAS G12V whi...

The peritoneum is the third most common site of recurrence in colorectal cancer (CRC)1,2. Colorectal cancer peritoneal metastases (CRPM) are associated with poorer overall survival (OS) compared to other metastatic sites3 and systemic anticancer treatment (SACT) alone offers 3-16 months median OS benefit4–7. Cytoreductive surgery (CRS) was shown to achieve OS of over 40 months in the phase III randomised controlled trial (RCT) (PRODIGE-7)8. The addition of Oxaliplatin heated intraperitoneal chemotherapy (HIPEC) did not significantly prolong OS (CRS alone=41.2 months, CRS+HIPEC=41.7 months; p=0.99).Consequently, international guidelines have recommended CRS for resectable CRPM, but advised against using HIPEC outside clinical trials8–10.